. Author manuscript; available in PMC: 2017 Jan 3.

Published in final edited form as: ACS Appl Mater Interfaces. 2016 Dec 2;8(49):33412–33422. doi: 10.1021/acsami.6b08153

Table 1.

Optimization of Antisense-miRNA-21 and Gemcitabine Loading in PEGylated-PLGA NPs

S no.	method	surfactant for emulsification	gemcitabine solvent	mean size (nm)^a	PDI^a	ζ potential^a	encapsulation efficiency gemcitabine/antisense-miRNA-21 (%)
1	w/o/w	3% Span 80, 1% Tween 80	water	148.4	0.163	−20.4	20.4/−
2	w/o/w	1% PVA	DCM/DMSO (10:1)	195.5	0.082	−8.6	24.4/−
3	w/o/w	1% Span 80, 1% PVA	DCM/DMSO (10:1)	230.8	0.242	−10.9	31.2/−
4	EDE	2% PVA	DCM/DMSO (10:1)	170.4	0.320	−7.5	27.4/−
5	w/o/w	2% PVA, 1% PVA	DCM/DMSO (10:1)	189.9	0.206	−9.4	28/−
6	w/o/w	1% Span 80, 1% PVA	DCM/DMSO (10:1)	204.9	0.155	−14.7	42/−
7	w/o/w	1% Span 80, 1% PVA	water	232.6	0.191	−12.9	24.0/−
8	w/o/w	1% Span 80, 1% PVA	DCM/DMSO (10:1)	215.1	0.189	−22.6	−/68.3
9	w/o/w	1% Span 80, 1% PVA	DCM/DMSO (10:1)	224.9	0.145	−18.8	40/64.2

Note: average of three DLS measurements.